Novan, Inc. Common Stock

NOVN

Börsenwert 2,64 Mio. $

Profil: Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 (berdazimer gel) as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.

Mitarbeiter: 90